Phase III Study of Vincristine Sulfate Liposome For Injection In Adults With Naïve Acute Lymphoblastic Leukemia

Inclusion Criteria:

* De novo untreated ALL patients diagnosed by the bone marrow morphology, immunophenotype.
* 65 ≥ Age (years) ≥ 18 , male or female,
* ECOG Performance status of 0, 1, or 2.
* Patients must fulfill the following laboratory values

  1. Total bilirubin ≤2 ULN (corrected for same age)
  2. AST and ALT ≤3 ULN ( corrected for same ages)
  3. Serum creatinine ≤2 ULN (corrected for same age)
* Didn't receive any of the following treatments within 4 weeks before inclusion: chemotherapy, radiotherapy, replacement therapy, operation, long term of glucocorticoid therapy（\>5 days）.
* No neurological disorders, no nerve or muscle injury (motor and sensory nerve).
* Patient must sign the informed consent and obey the protocol.

Exclusion Criteria:

* Atopy or allergic to multiple medicines or excipients.
* With serious complications that affect compliance.
* Serious organ dysfunctions or central nervous system disorders.
* Mixed phenotype acute leukemia, (T-B).
* Burkitt lymphoma/leukemia.
* Suspected or confirmed central nervous system leukemia.
* Diabetes.
* Received antifungal treatment with triazole agents within 1 month before inclusion.
* Reliance of antipyretic and analgesic medicines or psychotropic medicines.
* Undergoing or has undergone other clinical trials in 4 weeks before inclusion.
* Pregnant women, women of breast feeding or childbearing potential without contraception.
* Psychological disorders that affect signing consent.
* The investigators believe that patients who are not suitable for inclusion.